BioWorld MedTech

June 3, 2014

View Archived Issues

J&J emphasizing Chinese market in push to drive future company growth

Biomed Israel 2014: Biomed Israel conference celebrates innovation in an interactive environment

Inside the Beltway: House prods FDA over artificial pancreas in FY 2015 budget bill

Financings: Proteus Digital raises $120 million from new investors in funding round

M&A: St. Jude Medical completes acquisition of CardioMEMS

Agreements/contracts: Valley Health selects Medline as its distributor for medical/surgical supplies

World in Review: Medtronic launches Advisa and SureScan single chamber pacemakers

Hit Bits: MicroStrategy launches mobile app based on CMS, CDC, and census data

Products

People in Places

MDD's Cardiology Extra

Collaboration expected to PROMPT accelerated hereditary cancer research

There's still no cure for cancer but advances in gene sequencing technology have made it more possible to identify people with particularly high risk of developing cancer. Read More

MDD Perspectives: Stryker S&N acquisition rumors bolster recent orthopedic space

Today's news in brief

BioWorld

BioWorld briefs for April 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 15, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Antibodies binding to spike proteins on the surface of SARS-CoV-2 virus

Australian researchers discover new compound to treat long COVID

BioWorld

Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans....

Blood glucose chart and monitor, stethoscope, injector pen

Hightide’s HTD-1801 meets phase III endpoints in type 2 diabetes

BioWorld

Hightide Therapeutics Inc.’s berberine ursodeoxycholate (HTD-1801) met primary and secondary endpoints in the Symphony 1 and Symphony 2 phase III trials in type 2...